Handed-ness matters: right-handed chiral gold nanoparticles supercharge siRNA therapy against lung cancer

For years, gene-silencing therapies have promised to rewrite the rules of cancer treatment, yet a stubborn delivery problem has kept much of that promise out of reach. Small interfering RNA, or siRNA, can shut down virtually any disease-driving gene with exquisite precision, but the molecules are fragile, poorly taken up by cells, and easily degraded by enzymes in the bloodstream. Now, a team of researchers reporting in Materials Today Bio has unveiled an unexpectedly elegant solution that hinges on one of nature’s oldest design principles: chirality, the mirror-image handedness that pervades biology. By growing gold nanoparticles whose entire crystal structure is intrinsically left- or right-handed, and by pairing that handedness with a carefully chosen particle shape, the team built a delivery vehicle that shuttles siRNA into lung cancer cells with remarkable efficiency, silences a key immune-evasion gene, and shrinks tumors in living animals.

The significance of the work lies in a deceptively simple question that has rarely been asked: does the handedness of a nanoparticle’s atomic architecture, not just its surface chemistry, change how cells respond to it? Most chiral nanomaterials studied to date achieve their handedness by decorating otherwise symmetrical particles with chiral surface ligands. That approach works, but it carries risks, because loosely attached ligands can detach in the body, triggering toxicity or immune reactions. The new study took a different route. Using a seeded growth method, the researchers introduced either L- or D-cysteine as a chiral inducer while gold atoms deposited onto pre-formed seed crystals, coaxing the entire nanoparticle into a stable, mirror-image geometry that cannot shed its chirality because the chirality is baked into the crystal itself.

To disentangle the effects of handedness from those of particle shape, the team ran a complete two-by-two factorial experiment. They prepared gold nanoparticles in two distinct morphologies, multifaceted rhombi cuboctahedra and simple cubes, each grown with D-, L-, or racemic DL-chirality. Circular dichroism spectroscopy confirmed that the D- and L-versions produced near-perfect mirror-image optical signatures, with characteristic peaks near 600 nanometers for the rhombi cuboctahedra and around 650 nanometers for the cubes, while the racemic particles showed no chiral signal at all. Scanning electron microscopy revealed the left- and right-handed orientations of individual particles, and dynamic light scattering placed all variants in the 150 to 180 nanometer range, a size window known to favor endocytic uptake, which helped rule out size as a confounding variable.

With the particle library in hand, the researchers grafted on a minimal surface coating of methoxypolyethylene glycol thiol to confer water solubility and colloidal stability, then attached siRNA through robust gold-sulfur covalent bonds. Crucially, this gentle modification left the intrinsic chiroptical signatures intact, and the signals remained stable over a full week of monitoring. Energy-dispersive X-ray analysis found no detectable residues of the cationic surfactant used during synthesis, addressing a common toxicity concern. When free siRNA and nanoparticle-bound siRNA were incubated in serum, gel electrophoresis showed that the bound cargo remained undegraded, confirming that the gold scaffold shields its fragile payload from the nucleases that would otherwise destroy it within hours.

The first hint that handedness truly matters came from quantitative binding measurements. Using microscale thermophoresis, the team determined that D-handed rhombi cuboctahedra grip siRNA with a dissociation constant of about 0.099 micromolar, roughly 1.4-fold tighter than their L-handed twins. That modest difference in affinity proved to be a harbinger of much larger functional gaps downstream. In GFP-expressing lung cancer cells, the right-handed particles silenced the reporter gene far more effectively than their left-handed or racemic counterparts, and the rhombi cuboctahedral shape consistently outperformed the cube. The winning combination, D-handed rhombi cuboctahedra, achieved a GFP silencing efficiency of 71.1 percent, nearly 1.5 times the 48.2 percent delivered by the same right-handed chirality on a cubic scaffold.

To understand why mirror-image particles behave so differently, the researchers turned to high-throughput proteomics. Cells treated with siRNA-free D-, L-, or DL-particles showed clearly segregated protein expression profiles, with fifty proteins significantly differentially expressed between the D- and L-treatment groups. The affected pathways spanned endoplasmic reticulum function, membrane-bound organelles, cell adhesion, proteostasis, and transcriptional regulation, painting a picture in which the handedness of an inorganic crystal can reshape fundamental aspects of cellular machinery. The authors suggest that this chirality-specific proteome remodeling underlies the divergent uptake and trafficking behavior, engaging pro-endocytic machinery in some cases while leaving negative regulatory pathways untouched, though the precise membrane protein partners remain to be fully mapped.

Having identified the optimal carrier, the team loaded it with siRNA targeting PD-L1, the immune checkpoint molecule that many tumors overexpress to cloak themselves from immune attack. In H460 non-small cell lung cancer cells and A549 lung adenocarcinoma cells, the D-handed rhombi cuboctahedral formulation cut cell viability to roughly 20 to 40 percent at modest doses, while left-handed and racemic versions were far less potent. EdU proliferation assays and colony formation experiments confirmed the hierarchy, and control experiments with blank vectors, scrambled siRNA, and free siPD-L1 showed no significant inhibition, demonstrating that the effect flowed from genuine, carrier-protected gene delivery rather than nonspecific toxicity. Quantitative PCR revealed that the lead formulation knocked down PD-L1 mRNA by about 60 percent and STAT3 mRNA by about 55 percent in H460 cells, with immunofluorescence confirming a matching drop in PD-L1 protein.

Intriguingly, the silencing did not trigger the classical apoptotic executioner caspase-3, and Annexin V staining detected no significant apoptotic signal, suggesting the tumor cells succumb through non-apoptotic routes such as cell cycle arrest or senescence. The therapeutic effect also scaled with each cell line’s baseline PD-L1 expression, hinting that PD-L1 levels could serve as a biomarker to guide patient selection. In mice bearing subcutaneous H460 tumors, intratumoral injection of the D-handed formulation over twelve days markedly suppressed tumor growth and weight compared with all other groups, while body weights remained stable. Serum chemistry showed normal liver and kidney markers, mass spectrometry found no significant gold accumulation in major organs, and histological examination of heart, liver, spleen, lung, and kidney revealed no pathological abnormalities. In tumor tissue itself, PD-L1 staining dropped sharply and the proliferation marker Ki67 fell from roughly 60 percent to about 20 percent of tumor cells.

The study’s broader message is that chirality deserves a seat at the table as a fundamental design parameter for nanomedicine, on par with size, shape, and surface charge, and that intrinsic crystallographic handedness offers a durable, ligand-free way to exploit it. Because the chiral advantage emerges from the particle’s own geometry, the platform sidesteps the immunogenicity and instability that plague detachable targeting ligands, a meaningful step toward clinical translation. The authors are careful to note the limits of the current work: delivery was performed by local intratumoral injection, and systemic, intravenous delivery, the ultimate goal for treating metastatic disease, remains to be demonstrated. Even so, the demonstration that a simple change in mirror-image geometry can nearly double gene-silencing efficiency opens a striking new avenue for precision cancer therapy, one in which the handedness of matter itself becomes a therapeutic instrument.

Subject of Research: Chirality- and morphology-dependent siRNA delivery using intrinsically chiral gold nanoparticles for targeted lung cancer therapy

Article Title: Chirality and morphology-dependent siRNA delivery for targeted lung cancer therapy with intrinsically chiral gold nanoparticles

Article References: Li, Q., Xu, J., Zhang, E., Liu, C., Liu, W., Yan, K., Xu, D., & Wang, J. (2026). Chirality and morphology-dependent siRNA delivery for targeted lung cancer therapy with intrinsically chiral gold nanoparticles. Materials Today Bio, 41, Article 103745. https://doi.org/10.1016/j.mtbio.2026.103745

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103745

Keywords: siRNA delivery, chiral gold nanoparticles, PD-L1, lung cancer, nanomedicine, chirality, gene silencing, RNA interference, drug delivery, proteomics, tumor therapy, Materials Today Bio